Search

Your search keyword '"Caprioli, Marta"' showing total 25 results
Start Over Author "Caprioli, Marta"
25 results on '"Caprioli, Marta"'

1. High risk of misclassification of acute Parvovirus B19 infection into a systemic rheumatic disease.

Author

D'Onofrio, Bernardo, Virelli, Giulia, Pedrollo, Elisa, Caprioli, Marta, Riva, Marta, Renna, Daniela, Tonutti, Antonio, Luciano, Nicoletta, Ceribelli, Angela, Gremese, Elisa, Santis, Maria De, and Selmi, Carlo

Subjects
PARVOVIRUS diseases, PARVOVIRUS B19, RHEUMATISM, RHEUMATOID factor, VIRUS diseases, ANTIPHOSPHOLIPID syndrome, SYSTEMIC lupus erythematosus
Abstract

Objectives Parvovirus B19 most frequently causes epidemics of erythema infectiosum in children but also affects adults often leading to rheumatologic manifestations. While the serum profile allows the diagnosis, manifestations may mimic autoimmune conditions. The aim was to evaluate the proportion of patients with acute Parvovirus B19 infection fulfilling classification criteria for rheumatic diseases (RA and SLE). Methods We evaluated the clinical and serological features of 54 patients diagnosed with acute Parvovirus B19 infection seeking rheumatological attention between March and June 2024. Results The majority of patients were females (78%), with a mean (s. d.) age of 45 (13) years and 54% could not recall any known exposure. Fifty-one/54 (94%) had arthralgia, 27 (50%) arthritis (oligoarthritis in 67% of them), 24 (44%) fever, 19 (35%) skin rash and 7 (13%) purpura. Symptoms resolution generally occurred within 6 weeks. Complement levels were low in 14/33 (42%) tested patients, while the presence of serum ANA, anti-dsDNA, anti-phospholipids and rheumatoid factor was detected in 21/38 (55%), 10/26 (38%), 6/12 (50%) and 5/37 (13%) patients, respectively. Classification criteria for SLE were fulfilled in 93% of ANA-positive patients and RA criteria in 38% of patients with arthritis. Conclusions Parvovirus B19 infection manifestations may vary and nearly all patients with positive serum ANA fulfil the classification criteria for SLE. The risk of misclassification in patients with viral infection should not be overlooked. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases

Author

De Santis, Maria, primary, Motta, Francesca, additional, Isailovic, Natasa, additional, Clementi, Massimo, additional, Criscuolo, Elena, additional, Clementi, Nicola, additional, Tonutti, Antonio, additional, Rodolfi, Stefano, additional, Barone, Elisa, additional, Colapietro, Francesca, additional, Ceribelli, Angela, additional, Vecellio, Matteo, additional, Luciano, Nicoletta, additional, Guidelli, Giacomo, additional, Caprioli, Marta, additional, Rezk, Clara, additional, Canziani, Lorenzo, additional, Azzolini, Elena, additional, Germagnoli, Luca, additional, Mancini, Nicasio, additional, Lleo, Ana, additional, and Selmi, Carlo, additional

Published
2022
Full Text
View/download PDF

3. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.

Author

UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (MGD) Service de gastro-entérologie, Izadi, Zara, Brenner, Erica J, Mahil, Satveer K, Dand, Nick, Yiu, Zenas Z N, Yates, Mark, Ungaro, Ryan C, Zhang, Xian, Agrawal, Manasi, Colombel, Jean-Frederic, Gianfrancesco, Milena A, Hyrich, Kimme L, Strangfeld, Anja, Carmona, Loreto, Mateus, Elsa F, Lawson-Tovey, Saskia, Klingberg, Eva, Cuomo, Giovanna, Caprioli, Marta, Cruz-Machado, Ana Rita, Mazeda Pereira, Ana Carolina, Hasseli, Rebecca, Pfeil, Alexander, Lorenz, Hanns-Martin, Hoyer, Bimba Franziska, Trupin, Laura, Rush, Stephanie, Katz, Patricia, Schmajuk, Gabriela, Jacobsohn, Lindsay, Seet, Andrea M, Al Emadi, Samar, Wise, Leanna, Gilbert, Emily L, Duarte-García, Alí, Valenzuela-Almada, Maria O, Isnardi, Carolina A, Quintana, Rosana, Soriano, Enrique R, Hsu, Tiffany Y-T, D'Silva, Kristin M, Sparks, Jeffrey A, Patel, Naomi J, Xavier, Ricardo Machado, Marques, Claudia Diniz Lopes, Kakehasi, Adriana Maria, Flipo, René-Marc, Claudepierre, Pascal, Cantagrel, Alain, Goupille, Philippe, Wallace, Zachary S, Bhana, Suleman, Costello, Wendy, Grainger, Rebecca, Hausmann, Jonathan S, Liew, Jean W, Sirotich, Emily, Sufka, Paul, Robinson, Philip C, Machado, Pedro M, Griffiths, Christopher E M, Barker, Jonathan N, Smith, Catherine H, Yazdany, Jinoos, Kappelman, Michael D, Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection, Rahier, Jean-François, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (MGD) Service de gastro-entérologie, Izadi, Zara, Brenner, Erica J, Mahil, Satveer K, Dand, Nick, Yiu, Zenas Z N, Yates, Mark, Ungaro, Ryan C, Zhang, Xian, Agrawal, Manasi, Colombel, Jean-Frederic, Gianfrancesco, Milena A, Hyrich, Kimme L, Strangfeld, Anja, Carmona, Loreto, Mateus, Elsa F, Lawson-Tovey, Saskia, Klingberg, Eva, Cuomo, Giovanna, Caprioli, Marta, Cruz-Machado, Ana Rita, Mazeda Pereira, Ana Carolina, Hasseli, Rebecca, Pfeil, Alexander, Lorenz, Hanns-Martin, Hoyer, Bimba Franziska, Trupin, Laura, Rush, Stephanie, Katz, Patricia, Schmajuk, Gabriela, Jacobsohn, Lindsay, Seet, Andrea M, Al Emadi, Samar, Wise, Leanna, Gilbert, Emily L, Duarte-García, Alí, Valenzuela-Almada, Maria O, Isnardi, Carolina A, Quintana, Rosana, Soriano, Enrique R, Hsu, Tiffany Y-T, D'Silva, Kristin M, Sparks, Jeffrey A, Patel, Naomi J, Xavier, Ricardo Machado, Marques, Claudia Diniz Lopes, Kakehasi, Adriana Maria, Flipo, René-Marc, Claudepierre, Pascal, Cantagrel, Alain, Goupille, Philippe, Wallace, Zachary S, Bhana, Suleman, Costello, Wendy, Grainger, Rebecca, Hausmann, Jonathan S, Liew, Jean W, Sirotich, Emily, Sufka, Paul, Robinson, Philip C, Machado, Pedro M, Griffiths, Christopher E M, Barker, Jonathan N, Smith, Catherine H, Yazdany, Jinoos, Kappelman, Michael D, Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection, and Rahier, Jean-François

Abstract

Although tumor necrosis factor (TNF) inhibitors are widely prescribed globally because of their ability to ameliorate shared immune pathways across immune-mediated inflammatory diseases (IMIDs), the impact of COVID-19 among individuals with IMIDs who are receiving TNF inhibitors remains insufficiently understood. To examine the association between the receipt of TNF inhibitor monotherapy and the risk of COVID-19-associated hospitalization or death compared with other commonly prescribed immunomodulatory treatment regimens among adult patients with IMIDs. This cohort study was a pooled analysis of data from 3 international COVID-19 registries comprising individuals with rheumatic diseases, inflammatory bowel disease, and psoriasis from March 12, 2020, to February 1, 2021. Clinicians directly reported COVID-19 outcomes as well as demographic and clinical characteristics of individuals with IMIDs and confirmed or suspected COVID-19 using online data entry portals. Adults (age ≥18 years) with a diagnosis of inflammatory arthritis, inflammatory bowel disease, or psoriasis were included. Treatment exposure categories included TNF inhibitor monotherapy (reference treatment), TNF inhibitors in combination with methotrexate therapy, TNF inhibitors in combination with azathioprine/6-mercaptopurine therapy, methotrexate monotherapy, azathioprine/6-mercaptopurine monotherapy, and Janus kinase (Jak) inhibitor monotherapy. The main outcome was COVID-19-associated hospitalization or death. Registry-level analyses and a pooled analysis of data across the 3 registries were conducted using multilevel multivariable logistic regression models, adjusting for demographic and clinical characteristics and accounting for country, calendar month, and registry-level correlations. A total of 6077 patients from 74 countries were included in the analyses; of those, 3215 individuals (52.9%) were from Europe, 3563 individuals (58.6%) were female, and the mean (SD) age was 48.8 (16.5) years. The mo

Published
2021

4. Increased COVID-19 mortality in patients with rheumatic diseases: results from the CONTROL-19 study by the Italian Society for Rheumatology

Author

Zanetti, Anna, primary, Carrara, Greta, additional, Landolfi, Gianpiero, additional, Rozza, Davide, additional, Chighizola, Cecilia Beatrice, additional, Alunno, Alessia, additional, Andreoli, Laura, additional, Caporali, Roberto, additional, Gerli, Roberto, additional, Sebastiani, Gian Domenico, additional, Valesini, Guido, additional, Sinigaglia, Luigi, additional, Raffeiner, Bernd, additional, Lomater, Claudia, additional, Caprioli, Marta, additional, Fredi, Micaela, additional, Romeo, Nicoletta, additional, Cuomo, Giovanna, additional, Vadacca, Marta, additional, and Scirè, Carlo Alberto, additional

Published
2021
Full Text
View/download PDF

6. A case of psoriatic arthritis triggered by SARS-CoV-2 infection

Author

Novelli, Lucia, primary, Motta, Francesca, additional, Ceribelli, Angela, additional, Guidelli, Giacomo M, additional, Luciano, Nicoletta, additional, Isailovic, Natasa, additional, Vecellio, Matteo, additional, Caprioli, Marta, additional, Clementi, Nicola, additional, Clementi, Massimo, additional, Mancini, Nicasio, additional, Selmi, Carlo, additional, and De Santis, Maria, additional

Published
2020
Full Text
View/download PDF

8. SAT0267 SERUM ANTI-HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN ANTIBODY CHARACTERIZES SYSTEMIC SCLEROSIS WITH ANTI CENTROMERE ANTIBODY AND SEVERE RAYNAUD’S PHENOMENON WITH DIGITAL ULCERS

Author

Isailovic, Natasa, primary, Ceribelli, Angela, additional, Gorlino, Carolina, additional, Generali, Elena, additional, Santis, Maria De, additional, Caprioli, Marta, additional, Guidelli, Giacomo Maria, additional, Sarzi-Puttini, Piercarlo, additional, Satoh, Minoru, additional, and Selmi, Carlo, additional

Published
2019
Full Text
View/download PDF

9. The predictive role of ultrasound-detected tenosynovitis and joint synovitis for flare in patients with rheumatoid arthritis in stable remission. Results of an Italian multicentre study of the Italian Society for Rheumatology Group for Ultrasound: the STARTER study

Author

Filippou, Georgios, primary, Sakellariou, Garifallia, additional, Scirè, Carlo Alberto, additional, Carrara, Greta, additional, Rumi, Federica, additional, Bellis, Emanuela, additional, Adinolfi, Antonella, additional, Batticciotto, Alberto, additional, Bortoluzzi, Alessandra, additional, Cagnotto, Giovanni, additional, Caprioli, Marta, additional, Canzoni, Marco, additional, Cavatorta, Francesco Paolo, additional, De Lucia, Orazio, additional, Di Sabatino, Valentina, additional, Draghessi, Antonella, additional, Farina, Ilaria, additional, Focherini, Maria Cristina, additional, Gabba, Alessandra, additional, Gutierrez, Marwin, additional, Idolazzi, Luca, additional, Luccioli, Filippo, additional, Macchioni, Pierluigi, additional, Massarotti, Marco Sergio, additional, Mastaglio, Claudio, additional, Menza, Luana, additional, Muratore, Maurizio, additional, Parisi, Simone, additional, Picerno, Valentina, additional, Piga, Matteo, additional, Ramonda, Roberta, additional, Raffeiner, Bernd, additional, Rossi, Daniela, additional, Rossi, Silvia, additional, Rossini, Paola, additional, Scioscia, Crescenzio, additional, Venditti, Carlo, additional, Volpe, Alessandro, additional, and Iagnocco, Annamaria, additional

Published
2018
Full Text
View/download PDF

11. A case of psoriatic arthritis triggered by SARS-CoV-2 infection.

Author

Novelli, Lucia, Motta, Francesca, Ceribelli, Angela, Guidelli, Giacomo M, Luciano, Nicoletta, Isailovic, Natasa, Vecellio, Matteo, Caprioli, Marta, Clementi, Nicola, Clementi, Massimo, Mancini, Nicasio, Selmi, Carlo, and Santis, Maria De

Subjects
AUTOIMMUNE diseases, PSORIATIC arthritis, SPONDYLOARTHROPATHIES, COVID-19
Abstract

In the article, the authors present a case of a 27-year-old female with spondyloarthritis concomitantly with SARS-CoV-2 infection to discuss psoriatic arthritis triggered by said infection. In the case, the patient developed acute arthritis of the left ankle, dysgeusia and anosmia. Also cited are the subgroups of arthritis possibly linked to viral infections like reactive arthritis, viral arthritis and chronic arthritis.

Published
2021
Full Text
View/download PDF

12. Ultrasound-detected tenosynovitis independently associates with patient-reported flare in patients with rheumatoid arthritis in clinical remission: results from the observational study STARTER of the Italian Society for Rheumatology

Author

Bellis, Emanuela, primary, Scirè, Carlo Alberto, additional, Carrara, Greta, additional, Adinolfi, Antonella, additional, Batticciotto, Alberto, additional, Bortoluzzi, Alessandra, additional, Cagnotto, Giovanni, additional, Caprioli, Marta, additional, Canzoni, Marco, additional, Cavatorta, Francesco Paolo, additional, De Lucia, Orazio, additional, Di Sabatino, Valentina, additional, Draghessi, Antonella, additional, Filippou, Georgios, additional, Farina, Ilaria, additional, Focherini, Maria Cristina, additional, Gabba, Alessandra, additional, Gutierrez, Marwin, additional, Idolazzi, Luca, additional, Luccioli, Filippo, additional, Macchioni, Pierluigi, additional, Massarotti, Marco Sergio, additional, Mastaglio, Claudio, additional, Menza, Luana, additional, Muratore, Maurizio, additional, Parisi, Simone, additional, Picerno, Valentina, additional, Piga, Matteo, additional, Ramonda, Roberta, additional, Raffeiner, Bernd, additional, Rossi, Daniela, additional, Rossi, Silvia, additional, Rossini, Paola, additional, Sakellariou, Garifallia, additional, Scioscia, Crescenzio, additional, Venditti, Carlo, additional, Volpe, Alessandro, additional, Matucci-Cerinic, Marco, additional, and Iagnocco, Annamaria, additional

Published
2016
Full Text
View/download PDF

15. A validation study of a new classification algorithm to identify rheumatoid arthritis using administrative health databases: case-control and cohort diagnostic accuracy studies. Results from the RECord linkage On Rheumatic Diseases study of the Italian Society for Rheumatology.

Author

Carrara, Greta, Scirè, Carlo A., Zambon, Antonella, Cimmino, Marco A., Cerra, Carlo, Caprioli, Marta, Cagnotto, Giovanni, Nicotra, Federica, Arfè, Andrea, Migliazza, Simona, Corrao, Giovanni, Minisola, Giovanni, and Montecucco, Carlomaurizio

Abstract

Objectives: To develop and validate a new algorithm to identify patients with rheumatoid arthritis (RA) and estimate disease prevalence using administrative health databases (AHDs) of the Italian Lombardy region. Design: Case-control and cohort diagnostic accuracy study. Methods: In a randomly selected sample of 827 patients drawn from a tertiary rheumatology centre (training set), clinically validated diagnoses were linked to administrative data including diagnostic codes and drug prescriptions. An algorithm in steps of decreasing specificity was developed and its accuracy assessed calculating sensitivity/specificity, positive predictive value (PPV)/negative predictive value, with corresponding CIs. The algorithm was applied to two validating sets: 106 patients from a secondary rheumatology centre and 6087 participants from the primary care. Alternative algorithms were developed to increase PPV at population level. Crude and adjusted prevalence estimates taking into account algorithm misclassification rates were obtained for the Lombardy region. Results: The algorithms included: RA certification by a rheumatologist, certification for other autoimmune diseases by specialists, RA code in the hospital discharge form, prescription of disease-modifying antirheumatic drugs and oral glucocorticoids. In the training set, a four-step algorithm identified clinically diagnosed RA cases with a sensitivity of 96.3 (95% CI 93.6 to 98.2) and a specificity of 90.3 (87.4 to 92.7). Both external validations showed highly consistent results. More specific algorithms achieved >80% PPV at the population level. The crude RA prevalence in Lombardy was 0.52%, and estimates adjusted for misclassification ranged from 0.31% (95% CI 0.14% to 0.42%) to 0.37% (0.25% to 0.47%). Conclusions: AHDs are valuable tools for the identification of RA cases at the population level, and allow estimation of disease prevalence and to select retrospective cohorts. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

16. Development and First Validation of a Disease Activity Score for Gout

Author

Scirè, Carlo A., Carrara, Greta, Viroli, Cinzia, Cimmino, Marco A., Taylor, William J., Manara, Maria, Govoni, Marcello, Salaffi, Fausto, Punzi, Leonardo, Montecucco, Carlomaurizio, Matucci‐Cerinic, Marco, Minisola, Giovanni, Ariani, Alarico, Galossi, Alessandra, Lauriti, Ciro, Fracassi, Elena, Idolazzi, Luca, Bardelli, Marco, Selvi, Enrico, Tirri, Enrico, Furini, Federica, Inverardi, Flora, Calabrò, Andrea, Porta, Francesco, Bittelli, Raffaele, Venturino, Francesco, Capsoni, Franco, Prevete, Immacolata, Sebastiani, Giandomenico, Selmi, Carlo, Fabbriciani, Gianluigi, D'Avola, Giovanni, Botticella, Giulia, Serale, Francesca, Seminara, Giulia, D'Alessandro, Giuseppe, Santo, Leonardo, Longato, Lorena, Zaccara, Eleonora, Sinigaglia, Luigi, Atteritano, Marco, Broggini, Marco, Caprioli, Marta, Favero, Marta, Sallì, Salvatore, Scarati, Marco, Parisi, Simone, Malavolta, Nazzarena, Corvaglia, Stefania, Scarpato, Salvatore, and Veneto, Vittorio

Abstract

To develop a new composite disease activity score for gout and provide its first validation. Disease activity has been defined as the ongoing presence of urate deposits that lead to acute arthritis and joint damage. Every measure for each Outcome Measures in Rheumatology core domain was considered. A 3‐step approach (factor analysis, linear discriminant analysis, and linear regression) was applied to derive the Gout Activity Score (GAS). Decision to change treatment or 6‐month flare count were used as the surrogate criteria of high disease activity. Baseline and 12‐month followup data of 446 patients included in the Kick‐Off of the Italian Network for Gout cohort were used. Construct‐ and criterion‐related validity were tested. External validation on an independent sample is reported. Factor analysis identified 5 factors: patient‐reported outcomes, joint examination, flares, tophi, and serum uric acid (sUA). Discriminant function analysis resulted in a correct classification of 79%. Linear regression analysis identified a first candidate GAS including 12‐month flare count, sUA, visual analog scale (VAS) of pain, VAS global activity assessment, swollen and tender joint counts, and a cumulative measure of tophi. Alternative scores were also developed. The developed GAS demonstrated a good correlation with functional disability (criterion validity) and discrimination between patient‐ and physician‐reported measures of active disease (construct validity). The results were reproduced in the external sample. This study developed and validated a composite measure of disease activity in gout. Further testing is required to confirm its generalizability, responsiveness, and usefulness in assisting with clinical decisions.

Published
2016
Full Text
View/download PDF

17. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.

Author

Izadi, Zara, Brenner, Erica J., Mahil, Satveer K., Dand, Nick, Yiu, Zenas Z. N., Yates, Mark, Ungaro, Ryan C., Zhang, Xian, Agrawal, Manasi, Colombel, Jean-Frederic, Gianfrancesco, Milena A., Hyrich, Kimme L., Strangfeld, Anja, Carmona, Loreto, Mateus, Elsa F., Lawson-Tovey, Saskia, Klingberg, Eva, Cuomo, Giovanna, Caprioli, Marta, and Cruz-Machado, Ana Rita

Published
2021
Full Text
View/download PDF

18. Ultrasound-Detected Tenosynovitis Independently Associates with Flare in Patients with Rheumatoid Arthritis in Clinical Remission

Author

Bellis, Emanuela, Carrara, Greta, Scire, Carlo Alberto, Bortoluzzi, Alessandra, Batticciotto, Alberto, Adinolfi, Antonella, Cagnotto, Giovanni, Caprioli, Marta, Canzoni, Marco, Cavatorta, Francesco, Ceccarelli, Fulvia, Lucia, Orazio, Di Sabatino, Valentina, Draghessi, Antonella, Filippou, Georgios, Farina, Ilaria, Focherini, Maria Cristina, Frallonardo, Paola, Gabba, Alessandra, Gattamelata, Angelica, Gutierrez, Marwin, Luca Idolazzi, Luccioli, Filippo, Macchioni, Pierluigi, Massarotti, Marco, Mastaglio, Claudio, Menza, Luana, Mirabelli, Giulia, Muratore, Maurizio, Parisi, Simone, Picerno, Valentina, Piga, Matteo, Ramonda, Roberta, Raffeiner, Bernd, Rossi, Daniela, Rossini, Paola, Sakellariou, Garifallia, Scioscia, Crescenzio, Venditti, Carlo, Iagnocco, Annamaria, and Matucci-Cerinic, Marco

Subjects
rheumatoid arthritis

20. Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases

Author

Maria De Santis, Francesca Motta, Natasa Isailovic, Massimo Clementi, Elena Criscuolo, Nicola Clementi, Antonio Tonutti, Stefano Rodolfi, Elisa Barone, Francesca Colapietro, Angela Ceribelli, Matteo Vecellio, Nicoletta Luciano, Giacomo Guidelli, Marta Caprioli, Clara Rezk, Lorenzo Canziani, Elena Azzolini, Luca Germagnoli, Nicasio Mancini, Ana Lleo, Carlo Selmi, De Santis, Maria, Motta, Francesca, Isailovic, Natasa, Clementi, Massimo, Criscuolo, Elena, Clementi, Nicola, Tonutti, Antonio, Rodolfi, Stefano, Barone, Elisa, Colapietro, Francesca, Ceribelli, Angela, Vecellio, Matteo, Luciano, Nicoletta, Guidelli, Giacomo, Caprioli, Marta, Rezk, Clara, Canziani, Lorenzo, Azzolini, Elena, Germagnoli, Luca, Mancini, Nicasio, Lleo, Ana, and Selmi, Carlo

Subjects
Pharmacology, Infectious Diseases, antirheumatic agents, Drug Discovery, Immunology, mycophenolate mofetil, COVID-19, Pharmacology (medical), autoimmune diseases, vaccination
Abstract

The purpose of this study was to evaluate the efficacy and safety of the Moderna-1273 mRNA vaccine for SARS-CoV-2 in patients with immune-mediated diseases under different treatments. Anti-trimeric spike protein antibodies were tested in 287 patients with rheumatic or autoimmune diseases (10% receiving mycophenolate mofetil, 15% low-dose glucocorticoids, 21% methotrexate, and 58% biologic/targeted synthetic drugs) at baseline and in 219 (76%) 4 weeks after the second Moderna-1273 mRNA vaccine dose. Family members or caretakers were enrolled as the controls. The neutralizing serum activity against SARS-CoV-2-G614, alpha, and beta variants in vitro and the cytotoxic T cell response to SARS-CoV-2 peptides were determined in a subgroup of patients and controls. Anti-SARS-CoV-2 antibody development, i.e., seroconversion, was observed in 69% of the mycophenolate-treated patients compared to 100% of both the patients taking other treatments and the controls (p < 0.0001). A dose-dependent impairment of the humoral response was observed in the mycophenolate-treated patients. A daily dose of >1 g at vaccination was a significant risk factor for non-seroconversion (ROC AUC 0.89, 95% CI 0.80–98, p < 0.0001). Moreover, in the seroconverted patients, a daily dose of >1 g of mycophenolate was associated with significantly lower anti-SARS-CoV-2 antibody titers, showing slightly reduced neutralizing serum activity but a comparable cytotoxic response compared to other immunosuppressants. In non-seroconverted patients treated with mycophenolate at a daily dose of >1 g, the cytotoxic activity elicited by viral peptides was also impaired. Mycophenolate treatment affects the Moderna-1273 mRNA vaccine immunogenicity in a dose-dependent manner, independent of rheumatological disease.

Published
2022

21. A case of psoriatic arthritis triggered by SARS-CoV-2 infection

Author

Maria De Santis, Carlo Selmi, Francesca Motta, M. Caprioli, Nicasio Mancini, Giacomo Maria Guidelli, Matteo Vecellio, Nicoletta Luciano, L. Novelli, Natasa Isailovic, Angela Ceribelli, Massimo Clementi, Nicola Clementi, Novelli, Lucia, Motta, Francesca, Ceribelli, Angela, Guidelli, Giacomo M, Luciano, Nicoletta, Isailovic, Natasa, Vecellio, Matteo, Caprioli, Marta, Clementi, Nicola, Clementi, Massimo, Mancini, Nicasio, Selmi, Carlo, and De Santis, Maria

Subjects
2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), SARS-CoV-2, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Arthritis, Psoriatic, COVID-19, Arthritis, medicine.disease, Virology, Letter to the Editor (Case report), Psoriatic arthritis, Rheumatology, medicine, Humans, Pharmacology (medical), business, AcademicSubjects/MED00360
Published
2020

22. COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19)

Author

Carlo Alberto Scirè, Greta Carrara, Anna Zanetti, Gianpiero Landolfi, Cecilia Chighizola, Alessia Alunno, Laura Andreoli, Roberto Caporali, Roberto Gerli, Gian Domenico Sebastiani, Guido Valesini, Luigi Sinigaglia, Italian Registry of the Italian Society for Rheumatology (CONTROL-19), Cristiano Alessandri, Elena Marina Baldissera, Simone Barsotti, Francesca Bartoli, Elena Bartoloni, Maurizio Benucci, Francesca Bergossi, Daniela Bertolucci, Silvano Bettio, Giovanni Biasi, Luigi Bonfanti, Roberto Bortolotti, Alessandra Bortoluzzi, Francesco Campanaro, Corrado Campochiaro, Valentina Canti, Antonella Cappelli, Marta Caprioli, Davide Carboni, Antonio Carletto, Nicoletta Carlo-Stella, Valeria Carraro, Laura Castelnovo, Fulvia Ceccarelli, Maria Sole Chimenti, Edoardo Cipolletta, Manuela Ciprian, Fabrizio Conti, Edoardo Conticini, Francesca Crisafulli, Chiara Crotti, Giovanna Cuomo, Maurizio Cutolo 33, Marcello Dantes 34, Marco Di Carlo 28, Giacomo Emmi 13, Paola Faggioli 27, Ugo Fiocco 35, Franco Franceschini 30, Micaela Fredi 30, Angelica Gattamelata 36, Maria Chiara Gerardi 30, Giuseppe Germanò 37, Maria Gerosa 31, Giacomo Guidelli 23, Alessandro Giollo 24, Raffaella Greco 38, Florenzo Iannone 39, Maria Grazia Lazzaroni 30, Daniele Lini 30, Claudia Lomater 40, Matteo Longhi 41, Alfredomaria Lurati 42, Claudio Mastaglio 43, Liala Moschetti 30, Cecilia Nalli 30, Domenico Olivo 44, Giovanni Orsolini 24, Alejandro Ossandon 45, Viviana Antonella Pacucci 46, Salvatore Panaro 30, Simone Parisi 47, Silvia Piantoni 30, Maria Giovanna Portuesi 48, Paolo Prandini 38, Luca Quartuccio 49, Bernd Raffeiner 50, Rossella Reggia 51, Francesca Regola 30, Valeria Riccieri 36, Marta Riva 52, Nicoletta Romeo 53, Rosario Foti 54, Daniela Rossi 55, Cinzia Rotondo 56, Francesco Saccardo 57, Fausto Salaffi 28, Silvia Sartorelli 58, Piercarlo Sarzi Puttini 59, Gianantonio Saviola 60, Raffaele Scarpa 61, Isabella Scotti 31, Ettore Silvagni 15, Ferdinando Silveri 28, Francesca Romana Spinelli 9, Marika Tardella 28, Ilaria Tinazzi 62, Enrico Tirri 63, Monica Todoerti 64, Tania Ubiali 31, Marta Vadacca 65, Valentina Varisco 52, Alen Zabotti 49, Sara Zandonella Callegher 49, Giovanni Zanframundo 66, Stefania Zingarelli 30, Alberto Scirè, Carlo, Carrara, Greta, Zanetti, Anna, Landolfi, Gianpiero, Chighizola, Cecilia, Alunno, Alessia, Andreoli, Laura, Caporali, Roberto, Gerli, Roberto, Domenico Sebastiani, Gian, Valesini, Guido, Sinigaglia, Luigi, Registry of the Italian Society for Rheumatology (CONTROL-19), Italian, Alessandri, Cristiano, Marina Baldissera, Elena, Barsotti, Simone, Bartoli, Francesca, Bartoloni, Elena, Benucci, Maurizio, Bergossi, Francesca, Bertolucci, Daniela, Bettio, Silvano, Biasi, Giovanni, Bonfanti, Luigi, Bortolotti, Roberto, Bortoluzzi, Alessandra, Campanaro, Francesco, Campochiaro, Corrado, Canti, Valentina, Cappelli, Antonella, Caprioli, Marta, Carboni, Davide, Carletto, Antonio, Carlo-Stella, Nicoletta, Carraro, Valeria, Castelnovo, Laura, Ceccarelli, Fulvia, Sole Chimenti, Maria, Cipolletta, Edoardo, Ciprian, Manuela, Conti, Fabrizio, Conticini, Edoardo, Crisafulli, Francesca, Crotti, Chiara, Cuomo, Giovanna, Cutolo 33, Maurizio, Dantes 34, Marcello, Di Carlo 28, Marco, Emmi 13, Giacomo, Faggioli 27, Paola, Fiocco 35, Ugo, Franceschini 30, Franco, Fredi 30, Micaela, Gattamelata 36, Angelica, Chiara Gerardi 30, Maria, Germanò 37, Giuseppe, Gerosa 31, Maria, Guidelli 23, Giacomo, Giollo 24, Alessandro, Greco 38, Raffaella, Iannone 39, Florenzo, Grazia Lazzaroni 30, Maria, Lini 30, Daniele, Lomater 40, Claudia, Longhi 41, Matteo, Lurati 42, Alfredomaria, Mastaglio 43, Claudio, Moschetti 30, Liala, Nalli 30, Cecilia, Olivo 44, Domenico, Orsolini 24, Giovanni, Ossandon 45, Alejandro, Antonella Pacucci 46, Viviana, Panaro 30, Salvatore, Parisi 47, Simone, Piantoni 30, Silvia, Giovanna Portuesi 48, Maria, Prandini 38, Paolo, Quartuccio 49, Luca, Raffeiner 50, Bernd, Reggia 51, Rossella, Regola 30, Francesca, Riccieri 36, Valeria, Riva 52, Marta, Romeo 53, Nicoletta, Foti 54, Rosario, Rossi 55, Daniela, Rotondo 56, Cinzia, Saccardo 57, Francesco, Salaffi 28, Fausto, Sartorelli 58, Silvia, Sarzi Puttini 59, Piercarlo, Saviola 60, Gianantonio, Scarpa 61, Raffaele, Scotti 31, Isabella, Silvagni 15, Ettore, Silveri 28, Ferdinando, 9, Francesca Romana Spinelli, Tardella 28, Marika, Tinazzi 62, Ilaria, Tirri 63, Enrico, Todoerti 64, Monica, Ubiali 31, Tania, Vadacca 65, Marta, Varisco 52, Valentina, Zabotti 49, Alen, Zandonella Callegher 49, Sara, Zanframundo 66, Giovanni, and Zingarelli 30, Stefania

Abstract

OBJECTIVES: Italy was one of the first countries significantly affected by the coronavirus disease 2019 (COVID-19) epidemic. The Italian Society for Rheumatology promptly launched a retrospective and anonymised data collection to monitor COVID-19 in patients with rheumatic and musculoskeletal diseases (RMDs), the CONTROL-19 surveillance database, which is part of the COVID-19 Global Rheumatology Alliance. METHODS: CONTROL-19 includes patients with RMDs and proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) updated until May 3rd 2020. In this analysis, only molecular diagnoses were included. The data collection covered demographic data, medical history (general and RMD-related), treatments and COVID-19 related features, treatments, and outcome. In this paper, we report the first descriptive data from the CONTROL-19 registry. RESULTS: The population of the first 232 patients (36% males) consisted mainly of elderly patients (mean age 62.2 years), who used corticosteroids (51.7%), and suffered from multi-morbidity (median comorbidities 2). Rheumatoid arthritis was the most frequent disease (34.1%), followed by spondyloarthritis (26.3%), connective tissue disease (21.1%) and vasculitis (11.2%). Most cases had an active disease (69.4%). Clinical presentation of COVID-19 was typical, with systemic symptoms (fever and asthenia) and respiratory symptoms. The overall outcome was severe, with high frequencies of hospitalisation (69.8%), respiratory support oxygen (55.7%), non-invasive ventilation (20.9%) or mechanical ventilation (7.5%), and 19% of deaths. Male patients typically manifested a worse prognosis. Immunomodulatory treatments were not significantly associated with an increased risk of intensive care unit admission/mechanical ventilation/death. CONCLUSIONS: Although the report mainly includes the most severe cases, its temporal and spatial trend supports the validity of the national surveillance system. More complete data are being acquired in order to both test the hypothesis that RMD patients may have a different outcome from that of the general population and determine the safety of immunomodulatory treatments.

Published
2020

23. Development and first validation of a disease activity score for gout

Author

Scirè, Ca1, Carrara, G2, Viroli, C3, Cimmino, Ma4, Taylor, Wj5, Manara, M2, Govoni, M6, Salaffi, F7, Punzi, L8, Montecucco, C9, Matucci Cerinic M10, Minisola, G11, Collaborators Ariani A, Study Group for the Kick Off of the Italian Network for Gout S. t. u. d. y., Galossi, A, Lauriti, C, Fracassi, E, Idolazzi, L, Bardelli, M, Selvi, E, Tirri, E, Furini, F, Inverardi, F, Calabrò, A, Porta, F, Bittelli, R, Venturino, F, Capsoni, F, Prevete, I, Sebastiani, G, Selmi, C, Fabbriciani, G, D'Avola, G, Botticella, G, Serale, F, Seminara, G, D'Alessandro, G, Santo, L, Longato, L, Zaccara, E, Sinigaglia, L, Atteritano, Marco, Broggini, M, Caprioli, M, Favero, M, Sallì, S, Scarati, M, Parisi, S, Malavolta, N, Corvaglia, S, Scarpato, S, Veneto, V., Scire, C, Carrara, G, Viroli, C, Cimmino, M, Taylor, W, Manara, M, Govoni, M, Salaffi, F, Punzi, L, Montecucco, C, Matucci-Cerinic, M, Minisola, G, Ariani, A, Galossi, A, Lauriti, C, Fracassi, E, Idolazzi, L, Bardelli, M, Selvi, E, Tirri, E, Furini, F, Inverardi, F, Calabro, A, Porta, F, Bittelli, R, Venturino, F, Capsoni, F, Prevete, I, Sebastiani, G, Selmi, C, Fabbriciani, G, D'Avola, G, Botticella, G, Serale, F, Seminara, G, D'Alessandro, G, Santo, L, Longato, L, Zaccara, E, Sinigaglia, L, Atteritano, M, Broggini, M, Caprioli, M, Favero, M, Salli, S, Scarati, M, Parisi, S, Malavolta, N, Corvaglia, S, Scarpato, S, Veneto, V, Scirè, Carlo A, Carrara, Greta, Viroli, Cinzia, Cimmino, Marco A., Taylor, William J., Manara, Maria, Govoni, Marcello, Salaffi, Fausto, Punzi, Leonardo, Montecucco, Carlomaurizio, Matucci-Cerinic, Marco, Minisola, Giovanni, Ariani, Alarico, Galossi, Alessandra, Lauriti, Ciro, Fracassi, Elena, Idolazzi, Luca, Bardelli, Marco, Selvi, Enrico, Tirri, Enrico, Furini, Federica, Inverardi, Flora, Calabrò, Andrea, Porta, Francesco, Bittelli, Raffaele, Venturino, Francesco, Capsoni, Franco, Prevete, Immacolata, Sebastiani, Giandomenico, Selmi, Carlo, Fabbriciani, Gianluigi, D'Avola, Giovanni, Botticella, Giulia, Serale, Francesca, Seminara, Giulia, D'Alessandro, Giuseppe, Santo, Leonardo, Longato, Lorena, Zaccara, Eleonora, Sinigaglia, Luigi, Atteritano, Marco, Broggini, Marco, Caprioli, Marta, Favero, Marta, Sallì, Salvatore, Scarati, Marco, Parisi, Simone, Malavolta, Nazzarena, Corvaglia, Stefania, Scarpato, Salvatore, and Veneto, Vittorio

Subjects
Male, medicine.medical_specialty, Visual analogue scale, Aged, Arthralgia, Factor Analysis, Statistical, Female, Follow-Up Studies, Gout, Humans, Joints, Linear Models, Middle Aged, Pain Measurement, Patient Reported Outcome Measures, Regression Analysis, Reproducibility of Results, Uric Acid, Disease Progression, Severity of Illness Index, NO, disease activity, gout, patient perspective, 03 medical and health sciences, 0302 clinical medicine, gout, Rheumatology, Discriminant function analysis, Linear regression, Criterion validity, medicine, 030212 general & internal medicine, 030203 arthritis & rheumatology, business.industry, Construct validity, Regression analysis, Statistical, medicine.disease, Linear discriminant analysis, patient perspective, Physical therapy, Rheumatology, Factor Analysis, business, Factor Analysis, disease activity
Abstract

Objective To develop a new composite disease activity score for gout and provide its first validation. Methods Disease activity has been defined as the ongoing presence of urate deposits that lead to acute arthritis and joint damage. Every measure for each Outcome Measures in Rheumatology core domain was considered. A 3-step approach (factor analysis, linear discriminant analysis, and linear regression) was applied to derive the Gout Activity Score (GAS). Decision to change treatment or 6-month flare count were used as the surrogate criteria of high disease activity. Baseline and 12-month followup data of 446 patients included in the Kick-Off of the Italian Network for Gout cohort were used. Construct- and criterion-related validity were tested. External validation on an independent sample is reported. Results Factor analysis identified 5 factors: patient-reported outcomes, joint examination, flares, tophi, and serum uric acid (sUA). Discriminant function analysis resulted in a correct classification of 79%. Linear regression analysis identified a first candidate GAS including 12-month flare count, sUA, visual analog scale (VAS) of pain, VAS global activity assessment, swollen and tender joint counts, and a cumulative measure of tophi. Alternative scores were also developed. The developed GAS demonstrated a good correlation with functional disability (criterion validity) and discrimination between patient- and physician-reported measures of active disease (construct validity). The results were reproduced in the external sample. Conclusion This study developed and validated a composite measure of disease activity in gout. Further testing is required to confirm its generalizability, responsiveness, and usefulness in assisting with clinical decisions.

Published
2016

24. Increased COVID-19 mortality in patients with rheumatic diseases: results from the CONTROL-19 study by the Italian Society for Rheumatology.

Author

Zanetti A, Carrara G, Landolfi G, Rozza D, Chighizola CB, Alunno A, Andreoli L, Caporali R, Gerli R, Sebastiani GD, Valesini G, Sinigaglia L, Raffeiner B, Lomater C, Caprioli M, Fredi M, Romeo N, Cuomo G, Vadacca M, and Scirè CA

Subjects
Humans, Female, Middle Aged, Male, SARS-CoV-2, COVID-19, Rheumatology methods, Rheumatic Diseases epidemiology, Musculoskeletal Diseases epidemiology, Autoimmune Diseases epidemiology
Abstract

Objectives: To investigate differences in coronavirus disease 2019 (COVID-19) mortality between patients with rheumatic musculoskeletal diseases (RMD) and the general population in Italy., Methods: We analysed the data from the national surveillance study promoted by the Italian Society for Rheumatology (CONTROL-19 database) including patients with RMD and COVID-19 between 26 March 2020 and 29 November 2020, compared with official data from the Italian population (within the same period) adjusted for age, sex and geographic location. The main outcome of the analyses was mortality. The relationship between RMD and mortality was analysed using adjusted logistic models and sensitivity analyses were conducted to support the robustness of our results., Results: We included 668 RMD patients (62.7% with inflammatory arthritis, 28.6% with systemic autoimmune diseases), who had a mean age of 58.4 years and of which 66% were female. Compared to the general population, the RMD population showed an increased risk of death (OR 3.10 (95% CI 2.29-4.12)), independently from the differences in age and sex distribution. Even after considering the potential influence of surveillance bias, the OR was 2.08 (95% CI: 1.55-2.73). Such excess of risk was more evident in the subgroup of younger patients, and more consistent in women. Subjects with systemic autoimmune diseases showed a higher risk of death than patients with any other RMDs., Conclusions: Patients with RMD and COVID-19 infection evidenced a significant increase in mortality during the first pandemic phases in Italy. These findings support the need for strong SARS-CoV-2 prevention in patients with rheumatic diseases.

Published
2022
Full Text
View/download PDF

25. Churg-Strauss syndrome: a diagnosis not to be forgotten.

Author

Zanaboni D, Maccabruni A, Bonacci E, Caprioli M, Caporali R, and Mariani B

Subjects
Adrenal Cortex Hormones therapeutic use, Adult, Asthma drug therapy, Churg-Strauss Syndrome drug therapy, Churg-Strauss Syndrome pathology, Churg-Strauss Syndrome physiopathology, Humans, Immunosuppressive Agents therapeutic use, Intestinal Perforation surgery, Intestine, Small pathology, Male, Asthma complications, Churg-Strauss Syndrome diagnosis
Abstract

Churg-Strauss syndrome (CSS) is a peculiar form of vasculitis with involvement of small- and medium-size arteries, histologically characterized by necrotizing granulomas in vessel walls and in perivascular tissues. The Authors report a case of CSS occurred in a young man being treated with corticosteroids for a diagnosis of asthma. The patient was hospitalized because of fever, diarrhoea and abdominal pain; the first assessment showed leucocytosis and eosinophilia,increase in flogosis indexes and anti-pANCA antibodies positive. A few days later an acute peritonitis with multiple intestinal perforations occurred and a partial resection of small bowel was performed,followed by another resection of an ileal segment because of a new double perforation close to the previous intestinal anastomosis. In the bowel resection pieces necrotizing vasculitis and granulomatous infiltrates involving lymphocytes and eosino- phils were observed. Although the severe intestinal involvement and especially the symptoms necessitating iterative surgery were significant factors of poor prognosis the patient was successfully treated firstly with metylprednisolone only and then with monthly administration of immunosuppressive drugs combined with lower daily dose of steroids. The CSS diagnosis is not to be forgotten althoughits early clinical features can be frequently mistaken for an allergic disease; an early diagnosis can allow to perform the best treatment, to reach the disease remission and to improve the quality of life of the patients.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results